NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
RADNOR, Pa., Feb. 26, 2024 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering of a limited number of shares. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.